Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax

Pipeline

New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could lead to a “difficult path ahead” for Keros, according to Guggenheim analysts.

January 15, 2025

2 min read

Tristan Manalac

Policy

Pharmacy Benefits Managers Netted Extra $7.3B by Inflating Drug Prices: FTC

A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare and commercial claims alike.

January 15, 2025

2 min read

Dan Samorodnitsky

Business

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”

January 15, 2025

1 min read

Heather McKenzie

People

Lykos Loses Five Board Directors After FDA Rejection

Lykos Therapeutics is currently working out ways to fund an additional Phase III study for its MDMA-assisted PTSD therapy following an FDA setback last year.

January 15, 2025

2 min read

Tristan Manalac

Entrance to the U.S. Department of Health and Human Services in Washington, DC

Accelerated approval

Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.

January 15, 2025

2 min read

Tristan Manalac

Pictured: Aerial view of the San Francisco skyline

Pipeline

JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year.

January 15, 2025

4 min read

Tristan Manalac

Financier with a stack of coins in his hands. Art collage.

Venture capitalists

2024’s Top 7 VC Raises in Biotech

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to back-to-back series from obesity-focused Metsera that totaled more than $500M in a space that has garnered more than a fivefold increase in VC dollars this year.

January 15, 2025

7 min read

Ben Hargreaves

Earnings

Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.

January 14, 2025

2 min read

Dan Samorodnitsky